의료 분야 컴퓨터 비전 시장 : 컴포넌트 유형별, 기술 유형별, 도입 형태별, 용도별, 최종 사용자별 시장 예측(2026-2032년)

The Computer Vision in Healthcare Market is projected to grow by USD 8.49 billion at a CAGR of 15.17% by 2032.

Computer vision in healthcare is moving from experimental image analytics into routine clinical infrastructure across radiology, pathology, ophthalmology, dermatology, surgery, and remote patient monitoring. For healthcare providers, the technology converts medical images, video, and sensor feeds into structured clinical signals that support triage, detection, measurement, workflow automation, and longitudinal disease management.

Demand is reinforced by measurable healthcare pressures: the World Health Organization projects a global shortfall of 10 million health workers by 2030, while aging populations and chronic disease burdens continue to raise imaging volumes. In this environment, computer vision healthcare solutions help improve throughput, standardize image interpretation, and reduce avoidable delays without replacing clinician judgment.

Transformative Shifts in the Healthcare Vision Landscape

The landscape is shifting from single-point diagnostic algorithms toward integrated clinical decision support embedded in PACS, EHR, operating rooms, and patient-facing care pathways. FDA-cleared AI-enabled medical devices are increasingly concentrated in radiology, while adoption is widening into digital pathology, endoscopy, wound care, and hospital operations as providers seek measurable productivity gains.

Three changes define the market: multimodal AI that combines images with clinical records, edge-enabled imaging that brings analytics closer to devices, and cloud-native platforms that support continuous model monitoring. Health systems are prioritizing explainability, cybersecurity, workflow fit, and interoperability with DICOM, HL7, and FHIR standards to move from pilot projects to enterprise deployment.

Cumulative Impact of Artificial Intelligence

Artificial intelligence compounds the value of computer vision by improving lesion detection, segmentation, image reconstruction, anomaly prioritization, and predictive workflow routing. In clinical imaging, AI can help flag suspected stroke, pulmonary embolism, fractures, diabetic retinopathy, and cancer-related findings for faster review, while generative AI is beginning to support report drafting, image enhancement, and synthetic data generation under governance controls.

The cumulative impact is operational as much as clinical. AI-enabled computer vision reduces repetitive measurement tasks, supports quality assurance, and enables earlier intervention when combined with care protocols. However, safe scale requires bias testing across demographics, post-market surveillance, model version control, audit trails, and human-in-the-loop oversight aligned with FDA, EU MDR, HIPAA, and local data protection requirements.

Key Regional Insights

North America remains the most mature region for computer vision in healthcare due to high imaging utilization, established regulatory pathways, extensive clinical research networks, and the U.S. FDA's transparent database of AI/ML-enabled medical devices. Canada contributes through academic health AI networks and single-payer data assets, although procurement cycles can be slower across provincial systems.

Europe is advancing through structured regulation, including the EU Medical Device Regulation and the EU AI Act, which increases compliance expectations while improving trust in clinical AI. Asia-Pacific is scaling rapidly as China, Japan, South Korea, India, Australia, and ASEAN markets invest in digital hospitals, screening programs, telehealth, and AI-assisted diagnostics. Latin America shows rising demand in Brazil and Mexico for cost-efficient imaging access and radiology productivity, while the Middle East, led by GCC health transformation programs, invests in AI hospitals, smart diagnostics, and preventive care. Africa is earlier in adoption but has strong need for mobile screening, tuberculosis imaging, maternal health support, and cloud-enabled diagnostic access where specialist availability is limited.

Key Group Insights

Within ASEAN, computer vision adoption is tied to public hospital modernization, medical tourism hubs, and mobile-first access models, with Singapore serving as a regulatory and innovation anchor for digital health validation. GCC countries are using national health strategies to accelerate AI imaging, smart hospitals, and preventive care, especially in Saudi Arabia, the United Arab Emirates, and Qatar.

The European Union is shaping global compliance norms through privacy, AI risk classification, and medical device governance, making it a critical market for trustworthy AI design. BRICS economies offer large patient populations and expanding imaging infrastructure, with China, India, and Brazil particularly relevant for scalable deployment across public and private care settings. G7 markets lead in regulatory approvals, clinical validation, reimbursement evaluation, and enterprise procurement, while NATO countries increasingly link medical AI resilience with cybersecurity, defense health systems, secure data exchange, and cross-border interoperability.

Key Country Insights

The United States leads commercialization through FDA-cleared computer vision solutions, large health systems, cloud-enabled infrastructure, and reimbursement experimentation. Canada emphasizes responsible AI and provincial health data collaboration, while Mexico and Brazil show growing demand for affordable diagnostics, teleradiology, and radiology productivity. In Europe, the United Kingdom, Germany, France, Italy, and Spain are advancing AI imaging through national digital health strategies, cancer screening needs, and hospital modernization, while Russia maintains domestic AI initiatives shaped by local technology ecosystems and data sovereignty priorities.

China is scaling computer vision through hospital digitization, domestic AI development, and large imaging datasets, while India is using AI to expand diagnostics across underserved regions and high-volume private networks. Japan's aging population supports demand for imaging automation, assistive diagnostics, and care robotics; South Korea combines strong medtech manufacturing with digital hospital adoption; and Australia benefits from high-quality clinical research, telehealth experience, and remote-care use cases that support AI-enabled diagnostic access across dispersed populations.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated use cases with measurable outcomes, such as reduced turnaround time, improved triage accuracy, fewer missed follow-ups, and lower administrative burden. Procurement decisions should require peer-reviewed evidence, external validation, cybersecurity documentation, model monitoring plans, and integration proof with existing imaging and EHR workflows.

Providers should establish multidisciplinary AI governance teams involving clinicians, IT, compliance, legal, data science, and patient safety leaders. Successful scaling also depends on staff training, change management, algorithm performance audits, and vendor agreements that define data rights, update responsibilities, service levels, and post-deployment risk management.

Research Methodology

This executive summary is based on triangulation of publicly available regulatory databases, peer-reviewed clinical literature, government health strategies, medical device guidance, standards organizations, and industry adoption signals. Sources considered include FDA AI/ML-enabled medical device listings, WHO workforce and digital health publications, OECD and national health data, EU regulatory frameworks, and recognized interoperability standards such as DICOM, HL7, and FHIR.

The methodology emphasizes verified evidence over speculative forecasting. Insights were assessed for clinical relevance, regulatory credibility, geographic applicability, deployment feasibility, and alignment with healthcare buyer priorities, including patient safety, operational efficiency, privacy, and total cost of ownership.

Conclusion

Computer vision in healthcare is becoming a strategic capability for health systems seeking faster diagnosis, more efficient clinical workflows, and more equitable access to specialist expertise. The strongest opportunities are emerging where validated algorithms are integrated into routine care rather than used as isolated tools.

Organizations that combine clinical governance, interoperable architecture, responsible AI practices, and clear return-on-investment metrics will be best positioned for the next phase of adoption. As regulation matures and evidence expands, computer vision will increasingly define the digital front line of modern healthcare delivery.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Computer Vision in Healthcare Market, by Component Type

• 7.1. Hardware
  • 7.1.1. Camera Systems
  • 7.1.2. Compute Hardware
  • 7.1.3. Sensors
• 7.2. Services
  • 7.2.1. Integration And Deployment Services
  • 7.2.2. Support And Maintenance
• 7.3. Software
  • 7.3.1. Deep Learning Platforms
  • 7.3.2. Image Analysis Software
  • 7.3.3. Machine Learning Platforms

8. Computer Vision in Healthcare Market, by Technology Types

• 8.1. Artificial Intelligence
• 8.2. Deep Learning
• 8.3. Machine Learning

9. Computer Vision in Healthcare Market, by Deployment Modes

• 9.1. Cloud-Based
• 9.2. On Premise

10. Computer Vision in Healthcare Market, by Application

• 10.1. Diagnostic Imaging
• 10.2. Patient Monitoring & Rehabilitation
• 10.3. Research & Drug Discovery Support
• 10.4. Surgical Assistance & Intraoperative Guidance

11. Computer Vision in Healthcare Market, by End Users

• 11.1. Diagnostic Centers
• 11.2. Hospitals & Clinics
• 11.3. Research Laboratories

12. Computer Vision in Healthcare Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Computer Vision in Healthcare Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Computer Vision in Healthcare Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. AiCure, LLC
• 16.2. Alteryx, Inc.
• 16.3. Basler AG
• 16.4. Butterfly Network, Inc.
• 16.5. Caregility Corporation
• 16.6. Descartes Labs Inc.
• 16.7. Enlitic, Inc.
• 16.8. Fujitsu Limited
• 16.9. GE HealthCare Technologies Inc.
• 16.10. Google LLC by Alphabet Inc.
• 16.11. iCAD Inc.
• 16.12. InData Labs Group Ltd.
• 16.13. Innovacio Technologies
• 16.14. Intel Corporation
• 16.15. Intelligent Ultrasound Group
• 16.16. Iterative Health, Inc.
• 16.17. Keyence Corporation
• 16.18. Medtronic Inc.
• 16.19. Microsoft Corporation
• 16.20. NVIDIA Corporation
• 16.21. oxipit.ai
• 16.22. Tempus AI, Inc.
• 16.23. viso.ai AG